Tenderwize
Retour à la recherche

Open-House Discount Agreement Trastuzumab - Regions Lower Saxony, Bremen and Saxony-Anhalt

AOK Niedersachsen. Die Gesundheitskasse.·Hannover, Germany·Deadline Apr 21, 2027 · 237 days left·Open·Supplies·Framework
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Trastuzumab, ATC L01FD01 - Vertragsregionen Niedersachsen, Bremen und Sachsen-Anhalt

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No estimated value or guaranteed volume; contracts may be automatically suspended if another discount contract is signe...

Strict paper submission with hand signatures and required authorization documents; errors could invalidate offer.

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive discount agreements for Trastuzumab (ATC L01FD01) parenteral preparations in oncology for direct medical application to patients.
  • Two regional lots: Lower Saxony/Bremen and Saxony-Anhalt.
Afficher le résumé complet

Open-house non-exclusive discount agreement for the active substance Trastuzumab (ATC L01FD01) for parenteral preparations in oncology, for the regions of Lower Saxony/Bremen (Lot 1) and Saxony-Anhalt (Lot 2). This is not a competitive procurement but a voluntary open-house model where all eligible pharmaceutical entrepreneurs can join identical, non-negotiable contracts. Contracts run from 1 July 2025 to 30 June 2027. No estimated value is provided.

Risques

No estimated value or guaranteed volume; contracts may be automatically suspended if another discount contract is signe...

Strict paper submission with hand signatures and required authorization documents; errors could invalidate offer.

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG (German Medicines Act).
  • Company seat must be in Germany, EU, or EEA (§ 9 Abs. 2 AMG).

Administrative

  • Submission in paper form (two signed originals) plus electronic spreadsheet via email.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Award criterion is price (weight not specified).

Acheteur

Localisation

Hannover, DEU

Identifiant

AOK- Niedersachsen. Die Gesundheitskasse

Activité

Health

Lots (1)

LOT-0000

Open-House Discount Agreement Trastuzumab - Regions Lower Saxony, Bremen and Saxony-Anhalt

Two regional sub-lots: Regionallos 1 (Niedersachsen/Bremen) and Regionallos 2 (Sachsen-Anhalt). All eligible pharmaceutical entrepreneurs may conclude identical non-exclusive discount agreements for Trastuzumab parenteral preparations.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE929, Germany

Durée

Jun 2025 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Price

Date limite

Deadline Apr 21, 2027

Détails de la procédure

Date de publication
27 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
271454-2025

Appels d'offres similaires